A phase I/II single center, open-label, non-randomized study to evaluate intravenous injection of Tc99m tilmanocept into Kaposi's Sarcoma patients

Trial Profile

A phase I/II single center, open-label, non-randomized study to evaluate intravenous injection of Tc99m tilmanocept into Kaposi's Sarcoma patients

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Kaposi's sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Nov 2016 Status changed from planning to not yet recruiting, according to a Navidea Biopharmaceuticals media release.
    • 03 Nov 2016 According to a Navidea Biopharmaceuticals media release, the study protocol has been approved by Institutional Review Board.
    • 17 May 2016 According to a Navidea Biopharmaceuticals media release, this trial is expected to begin in the second half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top